Lab
Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings was paid $6.64M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 37% of everything it billed.
33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
OVERLAND PARK, KS 66210
OVERLAND PARK, KS 66210
33aNPI1679964613assigned 02/12/2015
33bProvider typeClinical Medical Laboratory
28Total paid$6.64M
24GClaims215,900
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Kansas
Rank by total paid#4 of 47
Median peer was paid$64K
This provider vs. median104×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,224 | $187K | |
| 2019 | 21,526 | $520K | |
| 2020 | 42,981 | $1.25M | |
| 2021 | 96,856 | $3.11M | |
| 2022 | 40,488 | $1.23M | |
| 2023 | 3,651 | $199K | |
| 2024incomplete | 3,174 | $142K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 37% | 37,573 | 32,218 | $2.47M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 13% | 36,615 | 34,902 | $879K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 13% | 36,366 | 34,613 | $872K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 11% | 13,508 | 11,993 | $699K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 7.4% | 21,570 | 20,326 | $492K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.5% | 15,480 | 13,977 | $302K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 4.3% | 18,794 | 17,750 | $287K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.8% | 11,814 | 11,343 | $249K |
| 88342 | 1.3% | 1,816 | 1,722 | $84K | |
| 88307 | <1% | 631 | 593 | $58K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,901 | 1,841 | $38K |
| 88141 | <1% | 3,086 | 2,922 | $37K |
28 more codes
| 88304 | <1% | 1,521 | $31K | |
| 87150 | <1% | 1,248 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,634 | $20K |
| 88142 | <1% | 1,269 | $14K | |
| 87625 | <1% | 748 | $10K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 219 | $10K |
| 86803 | <1% | 1,050 | $9K | |
| 87081 | <1% | 1,641 | $7K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 45 | $5K |
| 87340 | <1% | 720 | $5K | |
| 86592 | <1% | 1,768 | $5K | |
| 88341 | <1% | 68 | $5K | |
| 86780 | <1% | 428 | $4K | |
| 87088 | <1% | 508 | $3K | |
| 87186 | <1% | 285 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 826 | $1K |
| 86696 | <1% | 94 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 88 | $1K |
| 87077 | <1% | 187 | $945.39 | |
| 86695 | <1% | 82 | $589.32 | |
| 88302 | <1% | 38 | $583.35 | |
| 88312 | <1% | 12 | $583.17 | |
| 86850 | <1% | 72 | $417.99 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29 | $151.28 |
| 86901 | <1% | 71 | $148.24 | |
| 86900 | <1% | 71 | $148.24 | |
| 80053 | Comprehensive metabolic panel | <1% | 12 | $94.71 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12 | $78.34 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VICE PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.